



NEUREN PHARMACEUTICALS LIMITED - COMMENCEMENT OF OFFICIAL QUOTATION

Neuren Pharmaceuticals Limited was admitted to the Official List of Australian Stock Exchange Limited on Tuesday, 1 February 2005.

Official Quotation of 83,546,330 ordinary shares fully paid issued at \$0.40 per ordinary share will commence at 11.00 am E.D.S.T. on Thursday, 3 February 2005.

Quoted Securities 83,546,330 ordinary shares fully paid

Issue Price: \$0.40 per ordinary share

ASX Code: NEU

Date: 3 February 2005

Time: 11.00 am E.D.S.T

SEATS Abbreviation: NEUREN

ISIN: NZNEUE0001S8

Home Branch: Sydney

Industry Classification: 3520 Pharmaceuticals & Biotechnology

Registered Office: c/o Barnes Dowell James
122 Arthur Street
North Sydney 2060

Corporate office: Head Office
Level 3
2-6 Park Avenue
Grafton Auckland New Zealand

Phone: +64 (9) 367 7167

Fax: +64 (9) 367 7186

Web address: www.neurenpharma.com

Place of Incorporation: New Zealand

Company Secretary: Robert Waring

Share Registry: ASX Perpetual Registrars Limited
Level 4
333 Collins Street
Melbourne VIC 3000

Phone: 1300 554 474

Fax: (03) 8614 2903

Underwriter: Emerging Growth Capital Pty Ltd
Level 3
1 Castlereagh Street
Sydney NSW 2000
Phone: (02) 9222 1991
Fax: (02) 9222 2095

Balance Date: 31 December

CHESS: Participating. The Company will also operate an issuer-sponsored sub-register.

ASX restricted securities See below – Securities not quoted.

Activities: Biopharmaceutical company with a focus on neuroprotection and metabolism.

Securities not quoted 15,382,625 ordinary shares fully paid are classified by ASX as restricted securities and are to be held in escrow for a period of 24 months from commencement of official quotation.

7,643,672 options exercisable at \$0.39 New Zealand dollars and expiring on 31 March 2009 are to be held in escrow for a period of 24 months from commencement of official quotation.

1,071,045 ordinary shares fully paid are classified by ASX as restricted securities and are to be held in escrow for a period of 12 months from 30 June 2004.

For further information please refer to the Company's Prospectus dated 11 November 2004 and supplementary prospectus dated 23 December 2004.